| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 310.34 | 948 |
| Intrinsic value (DCF) | 23.16 | -22 |
| Graham-Dodd Method | 21.46 | -27 |
| Graham Formula | 1058.09 | 3475 |
Altamir SCA is a leading private equity firm based in Paris, France, specializing in direct and fund-of-fund investments in small and mid-cap companies across Europe, North America, and emerging markets. With a focus on sectors like healthcare, TMT (technology, media, and telecom), digital companies, retail, and business services, Altamir leverages its strategic partnerships with Apax Partners France and Amboise Investissement to drive growth in middle-market buyouts and growth capital investments. The firm targets companies with enterprise values between €50 million and €3 billion, emphasizing strong growth potential in niche healthcare segments, including medical devices, pharmaceuticals, and health services. Founded in 1995, Altamir SCA has built a reputation for disciplined investing, seeking majority or lead shareholder positions and aiming for exits within five years. Its diversified portfolio and deep sector expertise make it a key player in the European private equity landscape, appealing to investors seeking exposure to high-growth, unlisted companies.
Altamir SCA presents an attractive investment opportunity for those seeking exposure to private equity with a focus on European mid-market growth capital and buyouts. The firm’s strategic alignment with Apax Partners enhances deal flow and sector expertise, particularly in healthcare and digital industries. However, risks include exposure to illiquid private markets, economic downturns affecting portfolio valuations, and reliance on successful exits for returns. The firm’s dividend yield (1.08 EUR/share) and stable cash flow (€61.5M operating cash flow in FY 2024) provide some income stability, but its high debt (€238.5M) relative to cash reserves (€35.2M) warrants caution. Investors should weigh Altamir’s niche focus against broader private equity alternatives.
Altamir SCA’s competitive advantage lies in its exclusive partnership with Apax Partners, granting access to high-quality deal flow and co-investment opportunities in Europe’s mid-market segment. Its sector specialization—particularly in healthcare and digital services—allows for targeted value creation, while its fund-of-funds strategy provides diversification. However, Altamir faces stiff competition from larger global private equity firms with deeper capital pools and broader geographic reach. Its focus on French and Benelux markets, while a strength locally, limits exposure to faster-growing regions like Asia. The firm’s disciplined exit strategy (5-year horizon) mitigates holding-period risk but may lag behind rivals with more flexible timelines. Altamir’s smaller scale compared to mega-funds could also restrict its ability to compete for larger deals, though its middle-market niche offers less saturated opportunities.